Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ALRNASDAQ:BCELNASDAQ:EFTRNASDAQ:ELDN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALRAlere$1.32$0.00$34.41▼$51.00$43.05M0.8540,839 shsN/ABCELAtreca$0.09$0.09$0.05▼$1.20$3.57M1.034.61 million shsN/AEFTReFFECTOR Therapeutics$0.00$0.00$0.00▼$1.47$1K0.223,226 shs1 shsELDNEledon Pharmaceuticals$2.78-1.1%$3.04$2.30▼$5.54$166.47M-0.17276,196 shs199,424 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALRAlere0.00%0.00%0.00%0.00%0.00%BCELAtreca0.00%0.00%0.00%0.00%0.00%EFTReFFECTOR Therapeutics0.00%0.00%+50.00%-50.00%-99.97%ELDNEledon Pharmaceuticals0.00%-7.33%-9.15%-20.80%+6.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALRAlereN/AN/AN/AN/AN/AN/AN/AN/ABCELAtrecaN/AN/AN/AN/AN/AN/AN/AN/AEFTReFFECTOR TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AELDNEledon Pharmaceuticals2.8559 of 5 stars3.54.00.00.03.21.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALRAlere 0.00N/AN/AN/ABCELAtreca 0.00N/AN/AN/AEFTReFFECTOR Therapeutics 0.00N/AN/AN/AELDNEledon Pharmaceuticals 3.00Buy$9.00223.74% UpsideCurrent Analyst Ratings BreakdownLatest ALR, EFTR, ELDN, and BCEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$9.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALRAlere$934.59M0.05N/AN/A$5.72 per share0.23BCELAtrecaN/AN/AN/AN/A$2.01 per shareN/AEFTReFFECTOR Therapeutics$3.55M0.00N/AN/A($1.94) per share0.00ELDNEledon PharmaceuticalsN/AN/AN/AN/A$1.98 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALRAlere-$29.92M-$1.20N/AN/AN/A-5.34%-20.78%-9.02%N/ABCELAtreca-$97.16M-$2.50N/AN/AN/AN/A-157.90%-71.39%N/AEFTReFFECTOR Therapeutics-$35.81M-$13.08N/A∞N/AN/AN/AN/A7/28/2025 (Estimated)ELDNEledon Pharmaceuticals-$36.18M-$2.10N/AN/AN/AN/A-79.54%-41.62%8/18/2025 (Estimated)Latest ALR, EFTR, ELDN, and BCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ELDNEledon Pharmaceuticals-$0.28-$0.08+$0.20-$0.08N/AN/A3/20/2025Q4 2024ELDNEledon Pharmaceuticals-$0.32-$0.64-$0.32-$0.64N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALRAlereN/AN/AN/AN/AN/ABCELAtrecaN/AN/AN/AN/AN/AEFTReFFECTOR TherapeuticsN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALRAlere0.451.581.58BCELAtrecaN/A1.581.58EFTReFFECTOR TherapeuticsN/AN/AN/AELDNEledon PharmaceuticalsN/A13.9013.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALRAlere24.08%BCELAtreca37.47%EFTReFFECTOR Therapeutics57.67%ELDNEledon Pharmaceuticals56.77%Insider OwnershipCompanyInsider OwnershipALRAlere8.40%BCELAtreca11.30%EFTReFFECTOR Therapeutics4.70%ELDNEledon Pharmaceuticals12.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALRAlere10,40032.61 million29.87 millionOptionableBCELAtreca13039.62 million35.15 millionOptionableEFTReFFECTOR Therapeutics104.70 million4.48 millionNo DataELDNEledon Pharmaceuticals1059.88 million52.52 millionOptionableALR, EFTR, ELDN, and BCEL HeadlinesRecent News About These CompaniesAnalysts Issue Forecasts for ELDN Q1 EarningsJune 19 at 7:24 AM | marketbeat.comEledon Pharmaceuticals (NASDAQ:ELDN) Earns Buy Rating from Analysts at HC WainwrightJune 19 at 2:51 AM | americanbankingnews.comEledon Pharmaceuticals' (ELDN) "Buy" Rating Reaffirmed at HC WainwrightJune 18 at 8:05 AM | marketbeat.comBank of America Corp DE Increases Stock Holdings in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)June 13, 2025 | marketbeat.comMillennium Management LLC Invests $490,000 in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)June 9, 2025 | marketbeat.comEledon Pharmaceuticals (NASDAQ:ELDN) Downgraded by Wall Street Zen to "Sell"June 7, 2025 | marketbeat.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Down 12.3% in MayJune 4, 2025 | marketbeat.comJane Street Group LLC Makes New $504,000 Investment in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)May 31, 2025 | marketbeat.comWoodline Partners LP Boosts Stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)May 26, 2025 | marketbeat.comEledon Pharmaceuticals (NASDAQ:ELDN) Rating Increased to Hold at Wall Street ZenMay 24, 2025 | marketbeat.comWhat Makes Eledon Pharmaceuticals (ELDN) a New Buy StockMay 23, 2025 | zacks.com1,100,473 Shares in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Acquired by AWM Investment Company Inc.May 23, 2025 | marketbeat.comEquities Analysts Offer Predictions for ELDN Q2 EarningsMay 23, 2025 | marketbeat.comFrazier Life Sciences Management L.P. Invests $4.85 Million in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)May 23, 2025 | marketbeat.comZimmer Partners LP Has $3.09 Million Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)May 23, 2025 | marketbeat.comPoint72 Asset Management L.P. Purchases New Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)May 22, 2025 | marketbeat.comVelan Capital Investment Management LP Purchases New Position in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)May 21, 2025 | marketbeat.comFY2025 EPS Estimates for ELDN Boosted by Cantor FitzgeraldMay 21, 2025 | marketbeat.comQ2 EPS Estimate for Eledon Pharmaceuticals Lifted by AnalystMay 20, 2025 | marketbeat.comCantor Fitzgerald maintains Overweight on Eledon Pharmaceuticals stockMay 17, 2025 | uk.investing.comEledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial ResultsMay 14, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingTankers, Takedowns & Air Taxis: Insiders Are Buying These 3 NamesBy Leo Miller | June 10, 2025View Tankers, Takedowns & Air Taxis: Insiders Are Buying These 3 NamesASML Stock Might Be the Safest Chip Play at This PriceBy Gabriel Osorio-Mazilli | May 30, 2025View ASML Stock Might Be the Safest Chip Play at This PriceALR, EFTR, ELDN, and BCEL Company DescriptionsAlere NYSE:ALRAlere Inc. is a provider of health information through diagnostic tests. The Company's segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its joint venture with The Procter & Gamble Company (P&G). The Company's professional diagnostic solutions allow patients and their healthcare providers to work together to manage patients' conditions over the continuum of care, from the hospital to home. The Company offers lines of drugs-of-abuse tests, reagent systems and laboratory testing options.Atreca NASDAQ:BCELAtreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.eFFECTOR Therapeutics NASDAQ:EFTR$0.0003 0.00 (0.00%) As of 06/18/2025eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.Eledon Pharmaceuticals NASDAQ:ELDN$2.78 -0.02 (-0.89%) As of 06/18/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
